Decomposition of dichloroethane vapor in barrierless discharge

Decomposition of dichloroethane vapor in the low-temperature plasma of barrierless gas discharge was investigated. High-voltage pulsed power supply forms high-voltage pulses of microsecond duration (1…2,2 ms) with a pulse repetition rate of 1…15 kHz and amplitude up to 15 kV. That voltage pulse shape was not changed by dichlorethane vapors in the air. At the same time, as dichlorethane vapor concentration was increased, so the amplitude of current pulse was decreased. Active radicals formed as a result of decomposition are easily oxidized by atomic oxygen and ozone, which are simultaneously synthesized from the air in barrierless discharge. It was shown, that dichlorethane decomposition reached 100% at the power of 100 W.Исследовалось разложение паров дихлорэтана в низкотемпературной плазме безбарьерного газового разряда. Высоковольтный источник питания позволяет формировать импульсы микросекундной длительности (1...2,2 мкс) с частотой 15 кГц и амплитудой до 15 кВ. Импульс напряжения не изменялся для смеси паров дихлорэтана с воздухом относительно чистого воздуха. В то же время при росте концентрации дихлорэтана в воздухе происходило снижение амплитуды импульса тока. Активные радикалы, которые формируются в результате разложения дихлорэтана, легко окисляются атомарным кислородом и озоном, параллельно образующемся в безбарьерном разряде из воздуха. Показано, что при вложенной мощности порядка 100 Вт степень разложения дихлорэтана достигает 100 %.Досліджувалося розкладання парів діхлоретану у низькотемпературній плазмі безбар’єрного газового розряду. Високовольтне джерело живлення дозволяє формувати імпульси мікросекундної довжини (1...2,2 мкс) з частотою 15 кГц та амплітудою до 15 кВ. Імпульс напруги не змінюється для суміши парів діхлоретана з повітрям відносно чистого повітря. В той же час при зростанні концентрації діхлоретана в повітрі відбувалося зниження амплітуди імпульса струму. Активні радикали, що формуються внаслідок розкладання діхлоретану, легко окислюются атомарним киснем та озоном, що паралельно синтезуются з повітря. Показано, що при вкладеній потужності порядку 100 Вт ступінь розкладання діхлоретану сягає 100%

Validation of semi-automatic device UA-704 for self-measurement of blood pressure

Objective: To perform a clinical validation for a semi-automatic arm-type device DA-704 (A&D Company, Ltd., Tokyo, Japan) according to the British Hypertension Society protocol. Methods: Eighty-five study participants (37 men) were included. The mean age was 50.1 ± 17.0 years, systolic blood pressure range was 79-212 mmHg and diastolic blood pressure range was 43-118 mmHg. For each participant, three readings of the UA-704 were compared with simultaneous auscultatory measurements by two trained independent observers. The observers used a mercury calibrated sphygmomanometer and a dual stethoscope. The results were graded according to the 1993 British Hypertension Society protocol. Results: The average difference between mercury sphygmomanometer and UA-704 readings was -1.85 ± 4.26 mmHg (mean ± SD) for systolic blood pressure and -1.44 ± 3.97 mmHg for diastolic blood pressure. The proportions of values agreeing to within 5, 10 and 15 mmHg were 79.2%, 96.5% and 99.6% for systolic blood pressure and 86.7%, 96.9% and 99.6% for diastolic blood pressure for the observers and device (A/A grade for British Hypertension Society). Conclusions: For an adult population, the UA-704 device for self-measurement of blood pressure achieved a British Hypertension Society grade A/A and therefore can be recommended for home blood pressure monitoring. © 2005 Lippincott Williams & Wilkins

Validation of semi-automatic device UA-704 for self-measurement of blood pressure

Objective: To perform a clinical validation for a semi-automatic arm-type device DA-704 (A&D Company, Ltd., Tokyo, Japan) according to the British Hypertension Society protocol. Methods: Eighty-five study participants (37 men) were included. The mean age was 50.1 ± 17.0 years, systolic blood pressure range was 79-212 mmHg and diastolic blood pressure range was 43-118 mmHg. For each participant, three readings of the UA-704 were compared with simultaneous auscultatory measurements by two trained independent observers. The observers used a mercury calibrated sphygmomanometer and a dual stethoscope. The results were graded according to the 1993 British Hypertension Society protocol. Results: The average difference between mercury sphygmomanometer and UA-704 readings was -1.85 ± 4.26 mmHg (mean ± SD) for systolic blood pressure and -1.44 ± 3.97 mmHg for diastolic blood pressure. The proportions of values agreeing to within 5, 10 and 15 mmHg were 79.2%, 96.5% and 99.6% for systolic blood pressure and 86.7%, 96.9% and 99.6% for diastolic blood pressure for the observers and device (A/A grade for British Hypertension Society). Conclusions: For an adult population, the UA-704 device for self-measurement of blood pressure achieved a British Hypertension Society grade A/A and therefore can be recommended for home blood pressure monitoring. © 2005 Lippincott Williams & Wilkins

Validation of the TM-2564G device for in-hospital blood pressure measurement

OBJECTIVE: To perform clinical validation of the TM-2564G device (A&D Company, Ltd, Tokyo, Japan) for in-hospital blood pressure measurement according to the British Hypertension Society protocol. METHODS: The tests were carried out on 85 patients aged 19-82 years (41 male patients, mean age 50±19 years) with systolic blood pressure 75-219 mmHg and diastolic blood pressure 43-117 mmHg (mean 142±33/85±20 mmHg). For each patient, three readings of the TM-2564G device were compared with simultaneous auscultatory measurements by two trained independent observers. The observers used a mercury-calibrated sphygmomanometer and dual stethoscope. The results were graded according to the British Hypertension Society protocol 1993. RESULTS: The average difference was -1.85 mmHg for systolic blood pressure and -1.20 mmHg for diastolic blood pressure. The standard deviation of the difference between TM-2564G and the observers' results was 4.85 and 4.16 mmHg for systolic and diastolic blood pressures, respectively. Systolic blood pressure percentage of readings agreeing to within 5 mmHg was 75.7%, 10 mmHg 95.36% and 15 mmHg 99.6%, and for DBP 82.7, 97.6 and 99.8%, respectively. CONCLUSIONS: The TM-2564G device achieved A/A British Hypertension Society grade and can be recommended for in-hospital measurement of blood pressure. © 2005 Lippincott Williams & Wilkins, Inc

Validation of the TM-2564G device for in-hospital blood pressure measurement

OBJECTIVE: To perform clinical validation of the TM-2564G device (A&D Company, Ltd, Tokyo, Japan) for in-hospital blood pressure measurement according to the British Hypertension Society protocol. METHODS: The tests were carried out on 85 patients aged 19-82 years (41 male patients, mean age 50±19 years) with systolic blood pressure 75-219 mmHg and diastolic blood pressure 43-117 mmHg (mean 142±33/85±20 mmHg). For each patient, three readings of the TM-2564G device were compared with simultaneous auscultatory measurements by two trained independent observers. The observers used a mercury-calibrated sphygmomanometer and dual stethoscope. The results were graded according to the British Hypertension Society protocol 1993. RESULTS: The average difference was -1.85 mmHg for systolic blood pressure and -1.20 mmHg for diastolic blood pressure. The standard deviation of the difference between TM-2564G and the observers' results was 4.85 and 4.16 mmHg for systolic and diastolic blood pressures, respectively. Systolic blood pressure percentage of readings agreeing to within 5 mmHg was 75.7%, 10 mmHg 95.36% and 15 mmHg 99.6%, and for DBP 82.7, 97.6 and 99.8%, respectively. CONCLUSIONS: The TM-2564G device achieved A/A British Hypertension Society grade and can be recommended for in-hospital measurement of blood pressure. © 2005 Lippincott Williams & Wilkins, Inc

Ferrocene-containing tri- and tetranuclear cyclic copper(i) and silver(i) pyrazolates

New tri- and tetranuclear macrocyclic silver(i) and copper(i) 3-ferrocenyl-5-(trifluoromethyl)pyrazolates were prepared: [{(3-((η5-C5H4)Fe(η5-C5H5))-5-(CF3)-Pz}M]3 (M = Cu (1), Ag (2)) and [{(3-((η5-C5H4)Fe(η5-C5H5))-5-(CF3)-Pz}Cu]4 (3). The structures of compounds were established by X-ray diffraction analysis. In the crystalline state, a planar trinuclear silver-containing macrocycliс pyrazolate and a saddle-shaped tetranuclear copper-containing macrocycle are formed. The introduction of a bulky substituent, ferrocene, into the pyrazole ligand results in complete shielding of the acidic metal sites, which precludes the coordination of base molecules. © 2017, Springer Science+Business Media, LLC, part of Springer Nature

Ferrocene-containing tri- and tetranuclear cyclic copper(i) and silver(i) pyrazolates

New tri- and tetranuclear macrocyclic silver(i) and copper(i) 3-ferrocenyl-5-(trifluoromethyl)pyrazolates were prepared: [{(3-((η5-C5H4)Fe(η5-C5H5))-5-(CF3)-Pz}M]3 (M = Cu (1), Ag (2)) and [{(3-((η5-C5H4)Fe(η5-C5H5))-5-(CF3)-Pz}Cu]4 (3). The structures of compounds were established by X-ray diffraction analysis. In the crystalline state, a planar trinuclear silver-containing macrocycliс pyrazolate and a saddle-shaped tetranuclear copper-containing macrocycle are formed. The introduction of a bulky substituent, ferrocene, into the pyrazole ligand results in complete shielding of the acidic metal sites, which precludes the coordination of base molecules. © 2017, Springer Science+Business Media, LLC, part of Springer Nature